Ossicodone Aurobindo (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Ossicodone Aurobindo, is an opioid analgesic presented as a oral formulation for systemic use. It is prescribed for the management of moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Ossicodone Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ossicodone Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ossicodone Aurobindo is an opioid analgesic that acts on the central nervous system to relieve pain. - Acute postoperative pain: provides effective relief after surgical procedures. - Cancer‑related pain: helps control moderate to severe pain associated with malignancies. - Chronic non‑cancer pain: used when other analgesics are inadequate for persistent pain conditions.

Ossicodone Aurobindo may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: feeling of queasiness, sometimes with vomiting. - Drowsiness: increased sleepiness or fatigue. - Dizziness: light‑headed sensation, especially when standing. - Dry mouth: reduced salivary flow. - Pruritus: mild skin itching.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Opioid use disorder: dependence or addiction potential. - Seizures: rare occurrence of convulsive episodes. - Anaphylaxis: acute allergic reaction with rash, swelling, and airway compromise. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Ossicodone Aurobindo, clinicians should consider several safety measures. - Assess pain severity and prior opioid exposure: determine suitability before initiating therapy. - Monitor for respiratory depression: especially during dose titration and in opioid‑naïve patients. - Evaluate renal and hepatic function: adjust dosing in impairment. - Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol. - Educate patients on constipation management: use laxatives or stool softeners as needed. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ossicodone Aurobindo can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Benzodiazepines: combined use may cause profound respiratory depression. - Central nervous system depressants: additive sedation and decreased alertness. - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase oxycodine   - CYP3A4 inducers: increase metabolism, potentially reducing analgesic effect. - Anticholinergic agents: may exacerbate constipation. - Diuret‑tous‑   -